NCT07435467 · RECRUITING
Blood Biomarkers for Alzheimer Disease and Neuro-injury to Estimate the Association With Cognitive/Functional Decline and Mortality in a Real-world Population of GERiatric Hospitalized Patients (BAD-GER)
This is an observational study, not a treatment trial. Researchers are collecting blood samples from hospitalized elderly patients to test whether certain Alzheimer's and brain-injury biomarkers can predict who is likely to decline, be readmitted to the hospital, or die. No drug or intervention is involved. It is a real-world data study aimed at building a prognostic tool for clinical use.
Eligibility criteria
GROUP 1: Patients hospitalized for acute neurological disorders Inclusion criteria: * Inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis Exclusion criteria: * no informed consent GROUP 2: Patients hospitalized for non-neurological diseases with dementia Inclusion criteria: * inpatients with diagnosis of major neurocognitive disorder according to DSM-5 criteria (2013) Exclusion criteria: * Inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis * no informed consent GROUP 3: Patients hospitalized for non-neurological diseases without dementia Inclusion criteria: * inpatients with non-neurological diseases Exclusion criteria: * inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis * diagnosis of dementia * no informed consent
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-02-27